 WARREN, N.J.BUSINESS WIRETevogen Bio today announced positive topline results from its Proof-of-Concept POC clinical trial designed to evaluate the safety and feasibility of TVGN 489, the companys first clinical product of its precision T Cell therapy platform, for the treatment of acute high-risk COVID-19 patients. TVGN 489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8 ... Tevogen Bio Announces Positive Proof-of-Concept Clinical Tri... 